Nitroglycerin SL 0.3/0.4/0.6 mg — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Coronary Artery Disease/Angina

• Aspirin
• Clopidogrel
• Isosorbide mononitrate ER

About Nitroglycerin SL 0.3/0.4/0.6 mg

Nitroglycerin sublingual (SL) is a vital, fast-acting medication for managing sudden chest pain, or angina. If you live with this condition, having quick access to your medication is crucial. TheDrugClub understands this need and is committed to making essential prescriptions like nitroglycerin SL affordable and accessible for our members, often at no cost.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Nitroglycerin SL 0.3/0.4/0.6 mg is approved for (FDA label)

Nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin sublingual tablets are a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: October 15, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Nitroglycerin SL 0.3/0.4/0.6 mg (FDA label)

Nitroglycerin Sublingual Tablets are supplied as white, round, flat-faced tablets in three strengths: 0.3 mg (Coded with “N” on one side and “3” on the other) 0.4 mg (Coded with “N” on one side and “4” on the other) 0.6 mg (Coded with “N” on one side and “6” on the other) Sublingual tablets, 0.3 mg; 0.4 mg; 0.6 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 041f127e-5166-4484-bc1a-0a373d1187ae. SPL document ID: 2ac009f2-257f-4603-a1e8-c50aa9e31f4b. Label effective date: October 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nitroglycerin SL 0.3/0.4/0.6 mg (FDA label)

The following adverse reactions are discussed in more detail elsewhere in the label: • Hypotension [see Warnings and Precautions (5.2) ] • Headache [see Warnings and Precautions (5.4) ] • Hypersensitivity [see Contraindications (4.4) ] Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea, vomiting, weakness, diaphoresis, pallor, and collapse) may occur at therapeutic doses. Syncope due to nitrate vasodilatation has been reported. Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy. Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 041f127e-5166-4484-bc1a-0a373d1187ae. SPL document ID: 2ac009f2-257f-4603-a1e8-c50aa9e31f4b. Label effective date: October 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nitroglycerin SL 0.3/0.4/0.6 mg (FDA label)

• Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. ( 4.1 , 7.1 ) • Severe anemia ( 4.2 ) • Increased intracranial pressure ( 4.3 ) • Hypersensitivity to nitroglycerin or to other nitrates or nitrites or any excipient ( 4.4 ) • Circulatory failure and shock ( 4.5 ) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1) ]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat.

Source: FDA prescribing information (DailyMed). Set ID: 041f127e-5166-4484-bc1a-0a373d1187ae. SPL document ID: 2ac009f2-257f-4603-a1e8-c50aa9e31f4b. Label effective date: October 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Nitroglycerin SL 0.3/0.4/0.6 mg (FDA label)

• Tolerance: Excessive use may lead to tolerance. ( 5.1 ) • Hypotension: Severe hypotension may occur. ( 5.2 ) 5.1 Tolerance Excessive use may lead to the development of tolerance. Only the smallest dose required for effective relief of the acute angina attack should be used. A decrease in therapeutic effect of sublingual nitroglycerin may result from use of long-acting nitrates. 5.2 Hypotension Severe hypotension, particularly with upright posture, may occur with small doses of nitroglycerin particularly in patients with constrictive pericarditis, aortic or mitral stenosis, patients who may be volume-depleted, or are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris.

Source: FDA prescribing information (DailyMed). Set ID: 041f127e-5166-4484-bc1a-0a373d1187ae. SPL document ID: 2ac009f2-257f-4603-a1e8-c50aa9e31f4b. Label effective date: October 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Nitroglycerin SL 0.3/0.4/0.6 mg (FDA label)

Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use. ( 7.2 ) 7.1 PDE-5-Inhibitors and sGC-Stimulators Nitroglycerin sublingual tablets are contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. Nitroglycerin sublingual tablets are contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators. Concomitant use can cause hypotension. The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: 041f127e-5166-4484-bc1a-0a373d1187ae. SPL document ID: 2ac009f2-257f-4603-a1e8-c50aa9e31f4b. Label effective date: October 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.